Why Hims & Hers Health’s new COO appointment matters as FDA scrutiny and growth collide

Hims & Hers Health, Inc. (NASDAQ: HIMS) has announced that its Chief Commercial Officer, Mike Chi, will step into the role of Chief Operating Officer effective November 2, 2025. The move follows the decision by Nader Kabbani, who had been COO since May 2025, to transition into a strategic advisory role through July 2026. The company will also eliminate the separate Chief Commercial Officer position, consolidating operations, marketing, product, and commercial functions under Chi. The decision underscores a wider shift in how the telehealth player is managing scale, regulation, and execution in one of the fastest-evolving corners of healthcare.

Why did Hims & Hers Health decide to elevate Mike Chi to COO at this time?

The decision reflects a desire to unify execution and reduce silos at a time when digital health requires speed, coordination, and operational resilience. By combining oversight of product, marketing, operations, and commercial functions under Chi, Hims & Hers is betting that tighter integration will accelerate decision-making and strengthen accountability across its core business areas.

Chi has been with the company since April 2021 and brings more than two decades of experience in consumer internet, growth marketing, branding, and product strategy from companies such as Zola, INTERMIX, and Gilt Groupe. His background makes him an executive with fluency across customer acquisition, brand development, and product execution—skills that align with the company’s ambition to scale its subscriber base and expand internationally.

For Kabbani, the shift to an advisory role is notable given his pedigree at Amazon, Flexport, and Symbotic. His brief but important tenure at Hims & Hers involved bolstering operational frameworks and logistics. His advisory role through mid-2026 indicates continuity while signaling that the company sees greater value in consolidating leadership under Chi rather than maintaining split roles.

How does the company’s financial backdrop shape this leadership decision?

The appointment comes at a time of financial momentum for Hims & Hers Health. In the first quarter of 2025, the company reported revenue of $586 million, up 111% year-on-year. Net income reached $49.5 million, while adjusted EBITDA stood at $91.1 million. Subscriber growth also remained strong at 2.4 million, representing a 38% increase compared to the prior year. These results prompted the company to reaffirm its full-year revenue guidance of $2.3 to $2.4 billion and raise its adjusted EBITDA outlook to a range of $295 to $335 million.

On a trailing 12-month basis, revenue was close to $1.8 billion, with improving gross profit margins and positive net income. Analysts have noted that Hims & Hers is scaling profitably while managing subscription churn and customer acquisition costs, metrics that matter in the subscription-driven healthcare model. The company also maintains a relatively healthy balance sheet with over a billion dollars in cash and moderate leverage, which provides flexibility as it expands internationally.

Despite the growth, the stock has been volatile. Shares rallied over 90% in a three-month period earlier in 2025, outperforming many digital health peers. However, the stock has since cooled. The analyst consensus currently places HIMS at a “Hold,” with an average one-year price target of around $37, slightly below current levels. Bank of America has gone further, maintaining an Underperform rating and assigning a $28 price target, citing valuation concerns and noting that the stock trades at multiples far above sector averages.

Why are investors cautious about Hims & Hers despite strong revenue growth?

Investor caution stems largely from regulatory and execution risks. In September 2025, the U.S. Food and Drug Administration issued a warning letter to Hims & Hers regarding claims around its compounded semaglutide offerings. This marked a significant reputational and operational challenge, particularly as weight-loss drugs have become a high-profile growth vector for digital health firms. The FDA’s intervention adds pressure on Hims & Hers to refine its marketing practices, ensure compliance, and manage regulatory relationships more carefully.

In June 2025, Novo Nordisk also terminated its collaboration with Hims & Hers on Wegovy, its blockbuster weight-loss drug. That decision forced Hims & Hers to shift gears and rely more on its own compounded formulations, a higher-risk path that attracted both scrutiny and skepticism. The setback showed how dependent digital health players can be on pharmaceutical partnerships to validate supply chains and scale high-demand treatments.

These developments have made institutional investors wary. Growth-focused funds drove momentum during the company’s stock rally earlier this year, but more value-oriented institutions have since trimmed positions citing regulatory uncertainty. Analysts broadly agree that while top-line growth is strong, the company faces a narrower margin for error due to compliance scrutiny and elevated valuation multiples.

What are the risks and opportunities in consolidating leadership under one executive?

Consolidating operations, product, marketing, and commercial under Chi is a bold experiment in centralization. On the upside, it eliminates internal friction, reduces redundancy, and aligns the organization under a single operational vision. For a subscription-driven telehealth company, where customer acquisition must align seamlessly with fulfillment, clinical quality, and retention, such integration is attractive.

The risks are equally significant. Concentrating too much responsibility in one role can create bottlenecks if the organization lacks supporting depth. If the COO is stretched too thin, execution could suffer rather than improve. In addition, cultural adjustments may be required as teams adapt to reporting into a unified structure rather than separate verticals.

Compensation alignment is another area to watch. The company has disclosed that Chi’s compensation package will be reviewed by the Compensation Committee and subject to approval, signaling that incentives are being recalibrated to match his broader responsibilities. If those incentives are weighted too heavily toward top-line growth, the risk of compliance or margin issues could rise. Conversely, a balanced set of KPIs tied to profitability, churn, and regulatory compliance could create a healthier framework for execution.

How does this move connect to broader telehealth industry dynamics?

The consolidation at Hims & Hers fits into a larger trend across the digital health landscape. As telemedicine matures, companies are moving away from growth-at-all-costs toward operational discipline. The post-pandemic boom introduced millions of patients to online health platforms, but retention, regulation, and integration of services have become pressing issues.

Hims & Hers’ move mirrors strategies at other tech-enabled healthcare firms that centralize leadership to unify product and delivery. Competitors in the space are also grappling with FDA oversight, pressure to diversify revenue streams, and the challenge of proving sustainable profitability. By simplifying its executive structure, Hims & Hers aims to respond faster to competitive threats, regulatory developments, and consumer demand shifts.

The international push adds another layer. With the acquisition of U.K.-based telehealth platform Zava in June 2025, Hims & Hers gained access to markets in Germany, France, and Ireland. This expansion increases complexity, making a consolidated leadership model even more critical to synchronize operations across multiple regulatory environments.

What comes next for investors tracking Hims & Hers Health?

For investors, the next two earnings cycles will be telling. Markets will be closely watching Chi’s ability to manage the transition while maintaining momentum in revenue and subscriber growth. Analysts expect his first 90 days to include visible organizational changes, potentially new KPIs, and sharper execution around marketing and operations.

On the regulatory front, Hims & Hers will need to demonstrate compliance improvements, particularly in how it markets GLP-1 weight-loss drugs and other treatments. Any further FDA scrutiny could weigh heavily on the stock.

In terms of sentiment, HIMS remains a polarizing equity. Growth-focused investors view it as one of the few publicly traded telehealth players with scale and profitability, while cautious institutions point to valuation risks and regulatory uncertainty. For retail investors, the stock represents a high-beta exposure to digital health—one that could deliver outsized returns if execution is strong but could also falter quickly if compliance or growth slows.

A buy, sell, or hold decision therefore depends on risk tolerance. Investors comfortable with regulatory volatility and bullish on digital health disruption may see the leadership consolidation as a positive sign of operational discipline. More conservative investors may prefer to wait for clarity on FDA outcomes and margin trends before adding exposure.

The elevation of Mike Chi to COO marks more than a personnel change. It is a strategic pivot toward unified execution at a critical juncture for Hims & Hers Health. With strong revenue momentum but rising regulatory headwinds and valuation concerns, the next chapter will test whether streamlined leadership can deliver both growth and discipline. For a company that has built its identity on accessible, direct-to-consumer healthcare, the integration of commercial and operational functions may prove decisive in defining its future trajectory.